Cargando…

Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer

Targeted therapies have revolutionized the treatment for many patients with non-small cell lung cancer (NSCLC). Multiple new oral targeted therapies have been approved in the last decade; however, their overall efficacy may be reduced by poor adherence, treatment interruptions, or dose reductions du...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hines, Jacobi B., Bowar, Benjamin, Levine, Emma, Esposito, Alessandra, Garassino, Marina C., Bestvina, Christine M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253830/ https://www.ncbi.nlm.nih.gov/pubmed/37298380 http://dx.doi.org/10.3390/ijms24119429

Ejemplares similares

What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
por: Cameron, Robert B., et al.
Publicado: (2023)

Meeting an un-MET need: Targeting MET in non-small cell lung cancer
por: Michaels, Elena, et al.
Publicado: (2022)

Severity of COVID-19 in patients with lung cancer: evidence and challenges
por: Passaro, Antonio, et al.
Publicado: (2021)

AB012. Automated histologic subtyping of thymic epithelial tumors with deep learning
por: Dolezal, James M., et al.
Publicado: (2022)

Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents
por: Jordan, Emma J., et al.
Publicado: (2018)

Adverse events of targeted therapies approved for women's cancers
por: Saint-Ghislain, Mathilde, et al.
Publicado: (2021)

Rollout of ShangRing circumcision with active surveillance for adverse events and monitoring for uptake in Kenya
por: Odoyo-June, Elijah, et al.
Publicado: (2019)

Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting
por: Schotland, Peter, et al.
Publicado: (2020)

A Review of Methods for Monitoring Adverse Events in Pediatric Psychopharmacology Clinical Trials
por: Coates, Margaret, et al.
Publicado: (2018)

Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies
por: Guha, Avirup, et al.
Publicado: (2022)

Development of an adverse drug event network to predict drug toxicity
por: Wu, Qier, et al.
Publicado: (2020)

Adverse Events of DOACs in Children
por: Bosch, Alessandra, et al.
Publicado: (2022)

Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer
por: Li, Fei, et al.
Publicado: (2017)

Research progress on common adverse events caused by targeted therapy for colorectal cancer
por: Zhang, Bo, et al.
Publicado: (2018)

In Silico Profiling of Clinical Phenotypes for Human Targets Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2018)

Drug‐target‐ADR Network and Possible Implications of Structural Variants in Adverse Events
por: Dafniet, Bryan, et al.
Publicado: (2020)

Adverse events of targeted therapies reported by patients with cancer treated in primary care
por: Roger, Samuel, et al.
Publicado: (2021)

Adverse events: ART and the kidney: alterations in renal function and renal toxicity
por: Post, Frank
Publicado: (2014)

Adverse events with ayurvedic medicines- possible adulteration and some inherent toxicities
por: Paudyal, Buddhi, et al.
Publicado: (2019)

Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management
por: Apalla, Zoe, et al.
Publicado: (2021)

Response to “Evaluating Adverse Events in Databases”
por: Calapai, Fabrizio, et al.
Publicado: (2023)

Monitoring adverse events in Norwegian hospitals from 2010 to 2013
por: Deilkås, Ellen Tveter, et al.
Publicado: (2015)

Assessment and monitoring of biologic drug adverse events in patients with psoriasis
por: Hanley, Tessa, et al.
Publicado: (2016)

Drug target prediction using adverse event report systems: a pharmacogenomic approach
por: Takarabe, Masataka, et al.
Publicado: (2012)

Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies
por: Chen, Dong-Yi, et al.
Publicado: (2022)

Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data
por: Lee, Chae Won, et al.
Publicado: (2022)

Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer
por: Broggini, Massimo, et al.
Publicado: (2013)

Adverse Toxic Effects of Tyrosine Kinase Inhibitors on Non-Target Zebrafish Liver (ZFL) Cells
por: Kološa, Katja, et al.
Publicado: (2023)

Modeling Diagnostic Strategies to Manage Toxic Adverse Events following Cancer Immunotherapy
por: van Delft, Frederik, et al.
Publicado: (2021)

Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events
por: Teimouri, Arezou, et al.
Publicado: (2022)

Metabolomics Reveals Target and Off-Target Toxicities of a Model Organophosphate Pesticide to Roach (Rutilus rutilus): Implications for Biomonitoring
por: Southam, Andrew D., et al.
Publicado: (2011)

Prevention and management of adverse events related to regorafenib
por: De Wit, Mieke, et al.
Publicado: (2013)

Adverse Drug Events Monitoring of Live Attenuated Pandemic Influenza Vaccine
por: Akat, Pramod B, et al.
Publicado: (2011)

An unusual adverse event of azathioprine: Cutaneous small vessel vasculitis
por: Hanai, Shunichiro, et al.
Publicado: (2021)

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
por: Nichetti, Federico, et al.
Publicado: (2019)

The Role of MET in Resistance to EGFR Inhibition in NSCLC: A Review of Mechanisms and Treatment Implications
por: Feldt, Susan L., et al.
Publicado: (2023)

Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews
por: van Leeuwen, Marina T, et al.
Publicado: (2018)

Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets
por: Maciejewski, Mateusz, et al.
Publicado: (2017)

Patient voice on management of facial dermatological adverse events with targeted therapies: a qualitative study
por: Yagasaki, Kaori, et al.
Publicado: (2019)

Serious adverse events in patients with target-oriented blood pressure management: a systematic review
por: Frey, Lukas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1fa4bdneffs189apt3pucstvs5